David C Dale

List of Publications by Year in Descending Order

170 papers	10,619 citations	48 h-index	102 g-index
181 ext. papers	11,766 ext. citations	4.9 avg, IF	5.99 L-index

#	Paper	IF	Citations
170	Spectrum of Pathogenic Genetic Variants in a Large Cohort of North American Congenital and Cyclic Neutropenia Patients: A Report from the Severe Chronic Neutropenia International Registry. *Blood*, **2021**, 138, 2059-2059	2.2	
169	Safe and Efficient Engraftment of CRISPR-Based ELANE Mono-Allelic Knocked out HSCs in Mice: Evidence for a Novel Treatment for ELANE Neutropenia. *Blood*, **2021**, 138, 3122-3122	2.2	
168	Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study. *Blood*, **2021**, 138, 1121-1121	2.2	
167	The Experience of the Cooperation in Science and Technology European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias (COST EuNet-INNOCHRON) Action and the Sweden Experience in the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Era. *Blood*, **2021**, 138, 3125-3125	2.2	
166	Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment. *Blood*, **2021**, 138, 4310-4310	2.2	
165	Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States. *Blood*, **2021**, 138, 2186-2186	2.2	
164	Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia. *Blood*, **2021**,	2.2	7
163	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. *Nature Communications*, **2021**, 12, 1334	17.4	30
162	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. *Blood*, **2020**, 136, 35-36	2.2	
161	CRISPR Mediated ELANE Single-Allele Knock-out Restores Proliferation and Myeloid Differentiation of Neutropenia Patient Derived BM HSCs. *Blood*, **2020**, 136, 23-23	2.2	0
160	Neutropenia Is an Underrecognized Finding in Pediatric Primary Immunodeficiency Diseases: An Analysis of the United States Immunodeficiency Network Registry. *Journal of Pediatric Hematology/Oncology*, **2020**, 42, e601-e605	1.2	6
159	Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome. *Current Opinion in Hematology*, **2020**, 27, 11-17	3.3	1
158	Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry. *Current Opinion in Hematology*, **2020**, 27, 18-26	3.3	3
157	Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. *Blood*, **2020**, 136, 2994-3003	2.2	15
156	CRISPR/Cas9-mediated knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. *Haematologica*, **2020**, 105, 598-609	6.6	17
155	CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?. *Blood*, **2019**, 134, 435-435	2.2	
154	Family Studies of Whim Syndrome. *Blood*, **2019**, 134, 215-215	2.2	

153	Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies. *Blood*, **2019**, 134, 3589-3589	2.2	
152	Heterozygous Mutations of Clpb As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia. *Blood*, **2019**, 134, 433-433	2.2	
151	Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. *Current Opinion in Hematology*, **2019**, 26, 16-21	3.3	25
150	Neutropenia in Barth syndrome: characteristics, risks, and management. *Current Opinion in Hematology*, **2019**, 26, 6-15	3.3	17
149	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. *Clinical Lung Cancer*, **2018**, 19, e163-e169	4.9	18
148	Somatic mutations and clonal hematopoiesis in congenital neutropenia. *Blood*, **2018**, 131, 408-416	2.2	62
147	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. *Supportive Care in Cancer*, **2018**, 26, 7-20	3.9	32
146	Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome. *Blood*, **2018**, 132, 1102-1102	2.2	
145	Extended Genetic Testing in Severe Congenital Neutropenia May Identify Mutations That Inform Therapy. *Blood*, **2018**, 132, 2401-2401	2.2	0
144	CRISPR/Cas9 Knock-in HL60 Cells Closely Simulate Cellular and Functional Abnormalities of ELANE associated Neutropenia; Phenotype Rescue with MK-0339 Neutrophil Elastase Inhibitor. *Blood*, **2018**, 132, 3683-3683	2.2	
143	A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts. *Blood*, **2018**, 132, 1103-1103	2.2	
142	Myelodysplasia, Leukemia, Lymphoid Malignancies, and Other Cancers in Patients with Severe Chronic Neutropenia. *Blood*, **2018**, 132, 16-16	2.2	1
141	Neutropenia Is an Under-Recognized Finding in Pediatric Primary Immunodeficiency Diseases: An Analysis of the United States Immunodeficiency Network Registry. *Blood*, **2018**, 132, 3685-3685	2.2	
140	How I manage children with neutropenia. *British Journal of Haematology*, **2017**, 178, 351-363	4.5	47
139	Severe congenital neutropenias. *Nature Reviews Disease Primers*, **2017**, 3, 17032	51.1	139
138	Elastase inhibitors as potential therapies for -associated neutropenia. *Journal of Leukocyte Biology*, **2017**, 102, 1143-1151	6.5	17
137	Editorial for myeloid biology 2017. *Current Opinion in Hematology*, **2017**, 24, 1-2	3.3	
136	Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia. *New England Journal of Medicine*, **2017**, 377, 2290-2292	59.2	23

135	An update on the diagnosis and treatment of chronic idiopathic neutropenia. *Current Opinion in Hematology*, **2017**, 24, 46-53	3.3	30
134	X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome. *Blood*, **2017**, 130, 995-995	2.2	1
133	Long-Term Outcomes for G-CSF Treatment of Patients with Glycogen-Storage Disease Type Ib. *Blood*, **2017**, 130, 996-996	2.2	1
132	Peg-Filgrastim for the Treatment of Severe Chronic Neutropenia. *Blood*, **2016**, 128, 1332-1332	2.2	1
131	Termination and Frameshift Mutations in ELANE Are Associated with Adverse Outcomes in Patients with Severe Chronic Neutropenia. *Blood*, **2016**, 128, 1326-1326	2.2	2
130	Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome. *Blood*, **2016**, 128, 2681-2681	2.2	
129	Mutation Burden in Hematopoietic Stem Cells Is Not Increased in Congenital Neutropenia. *Blood*, **2016**, 128, 405-405	2.2	
128	TCIRG1 Mutations As a Cause for Chronic Neutropenia. *Blood*, **2016**, 128, 2511-2511	2.2	
127	The Effects of the Neutrophil Elastase Inhibitors MK0339 and Sivelestat on the Survival, Proliferation and Maturation of iPSC and HL60 Cells Expressing Mutant Neutrophil Elastase. *Blood*, **2016**, 128, 406-406	2.2	
126	Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project. *Genetic Epidemiology*, **2016**, 40, 470-4	2.6	8
125	How I diagnose and treat neutropenia. *Current Opinion in Hematology*, **2016**, 23, 1-4	3.3	24
124	Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. *Obstetrics and Gynecology*, **2015**, 125, 197-203	4.9	28
123	Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?. *Cancer Medicine*, **2015**, 4, 1153-60	4.8	16
122	The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. *Current Opinion in Hematology*, **2015**, 22, 3-11	3.3	85
121	Understanding, treating and avoiding hematological disease: better medicine through mathematics?. *Bulletin of Mathematical Biology*, **2015**, 77, 739-57	2.1	24
120	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. *SpringerPlus*, **2015**, 4, 396		10
119	The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects. *Cytokine*, **2015**, 72, 197-203	4	9
118	Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions. *Blood*, **2015**, 126, 2089-2089	2.2	6

117	Is There a Role for Anti-Neutrophil Antibody Testing in Predicting Spontaneous Resolution of Neutropenia in Young Children. *Blood*, **2015**, 126, 2211-2211	2.2	10
116	The North American Shwachman-Diamond Syndrome Registry: Genetically Undefined Shwachman-Diamond Syndrome. *Blood*, **2015**, 126, 3614-3614	2.2	
115	Barth Syndrome: An Under-Recognized Cause of Chronic Neutropenia. *Blood*, **2015**, 126, 2195-2195	2.2	
114	Application of Spectral Density/Periodogram Analysis to Serial Neutrophil Counts to Diagnose Cyclic Neutropenia. *Blood*, **2015**, 126, 4608-4608	2.2	
113	Long Term Outcomes for Patients with Cyclic Neutropenia Treated with Granulocyte Colony-Stimulating Factor (G-CSF). *Blood*, **2015**, 126, 996-996	2.2	1
112	Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. *Value in Health*, **2014**, 17, 739-43	3.3	2
111	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. *Blood*, **2014**, 123, 2229-37	2.2	109
110	Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. *Genetics in Medicine*, **2014**, 16, e1	8.1	207
109	TCIRG1-associated congenital neutropenia. *Human Mutation*, **2014**, 35, 824-7	4.7	30
108	Variable clinical presentation of Shwachman-Diamond syndrome: update from the North American Shwachman-Diamond Syndrome Registry. *Journal of Pediatrics*, **2014**, 164, 866-70	3.6	97
107	Evaluation and management of patients with isolated neutropenia. *Seminars in Hematology*, **2013**, 50, 198-206	4	114
106	Myelosuppression **2013**, 187-205		1
105	Colony-Stimulating Factors for Prevention and Treatment of Neutropenia and Infectious Diseases **2013**, 399-417		1
104	Neutropenia In Glycogen Storage Disease 1b (GSD1b). *Blood*, **2013**, 122, 2265-2265	2.2	1
103	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis. *Blood*, **2013**, 122, 444-444	2.2	1
102	TCIRG1 Associated Congenital Neutropenia. *Blood*, **2013**, 122, 440-440	2.2	
101	Barth Syndrome and Neutropenia. *Blood*, **2013**, 122, 3465-3465	2.2	
100	Clinical Outcomes for Patients with Severe Chronic Neutropenia Due to Mutations in the Gene for Neutrophil Elastase, ELANE. *Blood*, **2012**, 120, 3275-3275	2.2	1

99	rHuG-CSF for the Treatment of Severe Chronic Neutropenia **2012**, 279-291		
98	Early Studies of AMD3100/Plerixafor in Healthy Volunteers **2012**, 89-101		
97	The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. *Blood*, **2011**, 118, 4963-6	2.2	86
96	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer*, **2011**, 117, 1917-27	6.4	159
95	Cyclic and chronic neutropenia. *Cancer Treatment and Research*, **2011**, 157, 97-108	3.5	53
94	Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. *British Journal of Haematology*, **2010**, 150, 196-9	4.5	157
93	Outcomes of Pregnancies for Women with Severe Chronic Neutropenia with or without G-CSF Treatment.. *Blood*, **2010**, 116, 1490-1490	2.2	2
92	Neutrophil Elastase Mutations and the Risk of Leukemia In Patients with Cyclic and Congenital Neutropenia.. *Blood*, **2010**, 116, 3786-3786	2.2	2
91	Barth Syndrome and Severe Chronic Neutropenia.. *Blood*, **2010**, 116, 3787-3787	2.2	1
90	The many causes of severe congenital neutropenia. *New England Journal of Medicine*, **2009**, 360, 3-5	59.2	56
89	Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. *British Journal of Haematology*, **2009**, 147, 535-42	4.5	126
88	Genetic and molecular diagnosis of severe congenital neutropenia. *Current Opinion in Hematology*, **2009**, 16, 9-13	3.3	33
87	Granulocyte transfusion therapy: a new era?. *Current Opinion in Hematology*, **2009**, 16, 1-2	3.3	15
86	Advances in the treatment of neutropenia. *Current Opinion in Supportive and Palliative Care*, **2009**, 3, 207-12	2.6	17
85	Neutrophil biology and the next generation of myeloid growth factors. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2009**, 7, 92-8	7.3	5
84	The phagocytes: neutrophils and monocytes. *Blood*, **2008**, 112, 935-45	2.2	473
83	Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 109-18	7.3	173
82	Achieving a high-performance health care system: policies and positions of the American College of Physicians. *Endocrine Practice*, **2008**, 14, 502-4	3.2	

81	Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. *British Journal of Haematology*, **2008**, 140, 210-3	4.5	61
80	Neutropenia and Its Complications. *Translational Medicine Series*, **2008**, 1-19		
79	Spontaneous Recovery and Normalization of Blood Neutrophil Counts in Young Children with Severe Chronic Neutropenia. *Blood*, **2008**, 112, 3560-3560	2.2	
78	Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *Journal of Clinical Oncology*, **2007**, 25, 3158-67	2.2	522
77	What is WHIM syndrome?. *Blood*, **2007**, 109, 4-4	2.2	
76	Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. *Pharmacoeconomics*, **2007**, 25, 343-51	4.4	23
75	A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. *Blood*, **2007**, 110, 372-372	2.2	1
74	Myeloid growth factors. Clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2007**, 5, 188-202	7.3	47
73	Cyclic Neutropenia Is Not Associated with Transformation to MDS and AML.. *Blood*, **2007**, 110, 3306-3306	2.2	
72	Predictors of Transformation to Myelodysplasia/Acute Myelogenous Leukemia (MDS/AML) in Severe Congenital Neutropenia (SCN).. *Blood*, **2007**, 110, 3307-3307	2.2	
71	Recertification in internal medicine - the American experience. *Annals of the Academy of Medicine, Singapore*, **2007**, 36, 894-7	2.8	2
70	Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. *Cancer*, **2006**, 106, 2258-66	6.4	789
69	The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. *Supportive Cancer Therapy*, **2006**, 3, 220-31		113
68	Severe congenital neutropenia. *Seminars in Hematology*, **2006**, 43, 189-95	4	142
67	Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. *Journal of Pediatrics*, **2006**, 148, 633-6	3.6	43
66	The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood*, **2006**, 107, 4628-35	2.2	337
65	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. *Breast Cancer Research and Treatment*, **2006**, 100, 255-62	4.4	112
64	Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. *Supportive Care in Cancer*, **2006**, 14, 1184-94	3.9	9

63	Genotype-Phenotype Associations in Patients with Severe Congenital Neutropenia.. *Blood*, **2006**, 108, 502-502	2.2	
62	Mutations of the ELA2 Gene Found in Patients with Severe Congenital Neutropenia Induce the Unfolded Protein Response and Cellular Apoptosis.. *Blood*, **2006**, 108, 499-499	2.2	
61	Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.. *Blood*, **2006**, 108, 460-460	2.2	1
60	Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. *Transfusion*, **2005**, 45, 295-300	2.9	191
59	Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *Journal of Experimental Medicine*, **2005**, 201, 1307-18	16.6	916
58	A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.. *Blood*, **2005**, 106, 3328-3328	2.2	
57	Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy.. *Blood*, **2005**, 106, 3124-3124	2.2	
56	A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. *Blood*, **2005**, 106, 754-754	2.2	
55	Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. *Journal of Clinical Oncology*, **2004**, 22, 4302-11	2.2	253
54	Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. *Supportive Cancer Therapy*, **2004**, 1, 165-72		84
53	Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. *Blood*, **2004**, 103, 3355-61	2.2	72
52	Neutrophil elastase and neutropenia. *Blood*, **2004**, 103, 3993-3994	2.2	1
51	First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.. *Blood*, **2004**, 104, 2210-2210	2.2	7
50	Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin Lymphoma (NHL).. *Blood*, **2004**, 104, 3314-3314	2.2	2
49	Neutropenia and the Problem of Fever and Infection in Patients With Cancer **2004**, 219-233		
48	Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.. *Blood*, **2004**, 104, 4599-4599	2.2	
47	Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.. *Blood*, **2004**, 104, 89-89	2.2	3
46	Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2003**, 1, 440-54	7.3	66

45	Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. *Blood*, **2003**, 102, 2728-30	2.2	610
44	Molecular basis and therapy of disorders associated with chronic neutropenia. *Current Allergy and Asthma Reports*, **2003**, 3, 385-8	5.6	11
43	Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. *Experimental Hematology*, **2003**, 31, 372-81	3.1	45
42	Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. *Seminars in Oncology*, **2003**, 30, 3-9	5.5	27
41	Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. *American Journal of Hematology*, **2003**, 72, 82-93	7.1	288
40	Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. *The Journal of Supportive Oncology*, **2003**, 1, 11-7		23
39	Optimizing the management of chemotherapy-induced neutropenia. *Clinical Advances in Hematology and Oncology*, **2003**, 1, 679-84	0.6	8
38	Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. *Transfusion*, **2002**, 42, 1414-21	2.9	101
37	Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. *Journal of Infectious Diseases*, **2002**, 185, 1490-501	7	128
36	Colony-stimulating factors for the management of neutropenia in cancer patients. *Drugs*, **2002**, 62 Suppl 1, 1-15	12.1	127
35	Cyclic neutropenia. *Seminars in Hematology*, **2002**, 39, 89-94	4	117
34	Alpha Omega Alpha: encouraging excellence in medicine for more than a century. *The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha*, **2002**, 65, 4-21		1
33	Mutations in the neutrophil elastase gene in cyclic and congenital neutropenia. *Current Opinion in Immunology*, **2001**, 13, 535-8	7.8	40
32	Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. *Blood*, **2001**, 97, 147-53	2.2	71
31	Clinical implications of mutations of neutrophil elastase in congenital and cyclic neutropenia. *The American Journal of Pediatric Hematology/oncology*, **2001**, 23, 208-10		15
30	Modeling complex neutrophil dynamics in the grey collie. *Journal of Theoretical Biology*, **2000**, 204, 505-19	1.3	58
29	Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression ofbcl-x in neutrophil precursors. *Blood*, **2000**, 95, 320-327	2.2	101
28	Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. *Blood*, **2000**, 96, 2317-2322	2.2	459

27	Inhibition of in vivo neutrophil transmigration by a novel humanized anti-CD11/CD18 monoclonal antibody. *Cytokines, Cellular & Molecular Therapy*, **2000**, 6, 121-6		7
26	Use of G-CSF for granulocyte transfusion therapy. *Cytokines, Cellular & Molecular Therapy*, **2000**, 6, 89-95		8
25	Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. *Nature Genetics*, **1999**, 23, 433-6	36.3	392
24	Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic, and cyclical neutropenic patients before and during treatment with G-CSF. *Experimental Hematology*, **1999**, 27, 401-9	3.1	76
23	Hematopoietic dynamics in grey collies. *Experimental Hematology*, **1999**, 27, 1139-48	3.1	37
22	Neutrophils: Function and Role in Sepsis Syndrome. *Sepsis*, **1998**, 2, 107-117		7
21	Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. *American Journal of Hematology*, **1998**, 57, 7-15	7.1	62
20	Cyclical Neutropenia and Other Periodic Hematological Disorders: A Review of Mechanisms and Mathematical Models. *Blood*, **1998**, 92, 2629-2640	2.2	191
19	In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. *Journal of Infectious Diseases*, **1997**, 175, 1184-92	7	40
18	Chronic Thrombocytopenia Is Induced in Dogs by Development of Cross-Reacting Antibodies to the MpL Ligand. *Blood*, **1997**, 90, 3456-3461	2.2	24
17	Renewed interest in granulocyte transfusion therapy. *British Journal of Haematology*, **1997**, 98, 497-501	4.5	44
16	Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. *Drugs and Aging*, **1996**, 9, 37-47	4.7	47
15	Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. *American Journal of Medical Genetics Part A*, **1996**, 66, 413-22		64
14	Hematopoietic growth factors for the treatment of severe chronic neutropenia. *Stem Cells*, **1995**, 13, 94-100	5.8	23
13	Current Approach to the Management of Neutropenia. *Journal of Intensive Care Medicine*, **1995**, 10, 283-293		14
12	Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. *British Journal of Haematology*, **1994**, 88, 723-30	4.5	171
11	Aging and marrow neutrophil reserves. *Journal of the American Geriatrics Society*, **1994**, 42, 77-81	5.6	37
10	Cyclic neutropenia: natural history and effects of long-term treatment with recombinant human granulocyte colony-stimulating factor. *Cancer Investigation*, **1993**, 11, 219-23	2.1	23

9	Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. *New England Journal of Medicine*, **1989**, 320, 1306-11	59.2	296
8	Mechanism of canine cyclic hematopoiesis: the role of prostaglandin E in feedback regulation. *American Journal of Hematology*, **1983**, 14, 27-36	7.1	1
7	Human cyclic neutropenia: clinical review and long-term follow-up of patients. *Medicine (United States)*, **1981**, 60, 1-13	1.8	110
6	Chronic neutropenia. *Medicine (United States)*, **1979**, 58, 128-44	1.8	141
5	Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. *Arthritis and Rheumatism*, **1976**, 19, 618-22		96
4	Human Cyclic Neutropenia: Urinary Colony-stimulating Factor and Erythropoietin Levels. *Blood*, **1974**, 44, 257-262	2.2	20
3	Hematopoietic Growth Factors (Cytokines)498-507		
2	Neutropenia215-220		1
1	Neutropenia1-8		